High-Throughput High-Resolution Class I HLA Genotyping in East Africa

Rebecca N. Koehler1, Anne M. Walsh1, Eric E. Sanders-Buell1, Leigh Anne Eller2, Michael Eller2, Jeffrey R. Currier1, Christian T. Bautista1, Fred Wabwire-Mangen2, Michael Hoelscher4,5, Leonard Maboko5, Jerome Kim6, Nelson L. Michael6, Merlin L. Robb1, Francine E. McCutchan15, Gustavo H. Kijak1

1 United States Military HIV Research Program/Henry M. Jackson Foundation, Rockville, Maryland, United States of America, 2 Makerere University Walter Reed Research Project, Henry M. Jackson Foundation, Kampala, Uganda, 3 Makerere University, Kampala, Uganda, 4 Department of Infectious Diseases and Tropical Medicine, University of Munich, Munich, Germany, 5 Mbeya Medical Research Program, Mbeya, Tanzania, 6 United States Military HIV Research Program/Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America

Abstract

HLA, the most genetically diverse loci in the human genome, play a crucial role in host-pathogen interaction by mediating innate and adaptive cellular immune responses. A vast number of infectious diseases affect Africa, including HIV/AIDS, malaria, and tuberculosis, but the HLA genetic diversity in this region remains incompletely described. This is a major obstacle for the design and evaluation of preventive vaccines. Available HLA typing techniques, that provide the 4-digit level resolution needed to interpret immune responses, lack sufficient throughput for large immunoepidemiological studies. Here we present a novel HLA typing assay bridging the gap between high resolution and high throughput. The assay is based on real-time PCR using sequence-specific primers (SSP) and can genotype carriers of the 49 most common East African class I HLA-A, -B, and -C alleles, at the 4-digit level. Using a validation panel of 175 samples from Kampala, Uganda, previously defined by sequence-based typing, the new assay performed with 100% sensitivity and specificity. The assay was also implemented to define the HLA genetic complexity of a previously uncharacterized Tanzanian population, demonstrating its inclusion in the major East African genetic cluster. The availability of genotyping tools with this capacity will be extremely useful in the identification of correlates of immune protection and the evaluation of candidate vaccine efficacy.

Introduction

The human leukocyte antigen (HLA) loci, located in the major histocompatibility complex (MHC), encode cell-surface molecules that present peptides sampled from the proteome, mediating key immunological events: defining self-antigen tolerance and cellular immune responses to tumors and pathogens. Class I HLA-A, -B, and -C loci are essential for both innate and adaptive cellular immune responses. Their crucial interaction with T-cell receptors on cytotoxic T-lymphocytes (CTLs) mediates adaptive immune responses against viruses and intracellular parasites [1,2]. HLA are also ligands of killer immunoglobulin-like receptors (KIR) on the surface of natural killer cells, forming a bridge between innate and adaptive immunity [3].

The HLA are the most genetically diverse loci in the human genome [4]. When solely enumerated by variants that differ at the amino acid level (i.e., “4-digit” resolution level) the number of currently published class I HLA alleles amounts to 700 in the HLA-A locus, 1084 in the HLA-B locus, and 371 in the HLA-C locus [5]. While these counts reflect worldwide surveys, only a subset of these alleles is usually found in any given global indigenous population [6]. At the global scale, the complex genetic makeup of the HLA bears the marks of the history of each population [7], including several waves of migration [8], different levels of admixture with other populations [9], and changes in their effective population size [10]. In addition, one of the strongest forces molding HLA complexity has been the selective pressure exerted by numerous pathogens [8,11] which is most evident in populations that have maintained larger effective population sizes for longer periods of time [12], as is the case for East African populations [13].

East African populations are heavily affected by infectious diseases [14], including malaria [15], tuberculosis [16], HIV/AIDS [17], leishmaniasis [18], schistosomiasis [19], and viral hemorrhagic fever [20,21,22]. For each of these diseases, HLA diversity plays a crucial role in the host-pathogen interaction, affecting the rates of disease acquisition and outcome [23,24,25,26,27,28,29,30,31]. Nevertheless, and with few excep-
tions [32,33,34,35,36,37,38,39,40], class I HLA genetic diversity of East African populations remains incompletely described, one of the main impediments for the design and evaluation of preventive vaccines for this region [41].

Immunoeppidemiological studies aimed at supporting vaccine development require the assessment of large cohorts [42]. However, the level of diversification within HLA allele families in East African populations [32,33] and its consequences on antigen presentation and disease course [31] call for high-resolution HLA genotyping. Currently available techniques, such as sequence-based typing (SBT), PCR using sequence-specific primers (SSP), and PCR using sequence-specific oligonucleotide probes (SSOP), meet only some of these requirements. SBT provides high-resolution typing, but at high cost and low throughput, and is not able to discern cis/trans linkage of sequence motifs, which can result in ambiguities in allele calls [43]. PCR-SSP is able to identify linkage among polymorphisms [44], but PCR-SSP and PCR-SSOP have a lower level of resolution than SBT and require time-consuming post-PCR processing, significantly reducing their throughput.

Here we present the development, validation, and implementation of an assay to support molecular epidemiology studies capable of discriminating carriers of the most frequent class I HLA-A, -B, and -C alleles in East Africa from non-carriers, and that bridges the gap between high-throughput/low-cost and high-resolution HLA typing. The novel platform is based on real-time PCR-SSP and performs with high sensitivity and specificity in high-throughput genotyping of the 49 most common class I HLA-A, -B, and -C alleles in East Africa, providing 80–90% population coverage. Thus, it is an ideal tool for immunoeppidemiological studies.

Results

Assay scope and principle

To date, 36, 55, and 24 HLA-A, -B, and -C alleles have been reported in East African populations [32,33], respectively. There is a coincidence in the alleles constituting the major variants in Kenyan Luo, Kenyan Nandi, and Ugandans, despite some differences in the frequencies at which each allele variant is represented [32,33]. When these alleles were sorted in descending order of abundance and the cumulative allele frequencies were calculated for each locus, their layout resembled a logarithmic distribution, with less than half of the allelic variants providing large population coverage and the remainder found at very low frequencies (Figure 1). Based on this distribution of genetic variation, we focused on discrimination of the 14 most frequent HLA-A, 23 HLA-B, and 12 HLA-C alleles that provide population coverage ranging from 80 to 90% in East African populations (see insets in Figure 1). None of the minor alleles was represented at allelic frequencies larger than 0.03, and even though they might have an impact at the individual level they are unlikely to have a significant influence at the population level [45]; due to statistical power constraints these minor alleles are of only marginal interest in molecular epidemiological studies. Furthermore, by limiting the scope of the assay to the major alleles in these populations, we could attempt to achieve a genotyping platform with a higher throughput, higher specificity, and higher sensitivity.

Assay layout

The layout of the assay is summarized in Figure 2. Genomic areas spanning exon 2 through exon 3 of the class I HLA-A, -B, and -C were respectively amplified in three separate first round PCRs, one per locus, using locus-specific primers [46,47]. This initial amplification step prevented the subsequent interference from paralogous loci (Figure S1). These amplicons were diluted and used as templates in subsequent real-time PCR-SSPs. Each real-time PCR-SSP consisted of a pair of forward and reverse sequence-specific primers, whose amplification was monitored by a fluorescent TaqMan probe targeting an invariant region in the reverse exon within the same first-round amplicon template. The difference in amplification efficiency between the sequence-specific and the internal standardization reactions, measured as the respective Ct values, was used to assign a positive or negative reactivity to each reaction. In total, 31, 50, and 26 different primers and 7 probes (Table 1, Table 2 and Table 3) were utilized in 20 HLA-A, 46 HLA-B, and 15 HLA-C typing reactions, respectively (Table 4, Table 5 and Table 6). While some of the reactions were specific for several alleles (e.g., reactions 016 and 018 in the HLA-A locus), other reactions exhibited reactivity with only few (e.g., reactions 008 and 009 in the HLA-A locus) or a single allele (e.g., reactions 001 and 003 in the HLA-A locus) (Table 7, Table 8 and Table S1).

The arrays of reactions were designed so that each of the 105 HLA-A and 78 HLA-C individual genotypes comprising the addressed alleles had a unique aggregate reactivity pattern (Table S2, Table S3, and Table S4). In the case of HLA-B, due to the allele complexity of the locus, 273/276 distinct patterns were attained, as the following pairs of addressed genotypes shared common reactivity patterns: B*4201/B*4202 and B*4201/B*4201/B*4201; B*0702/B*4202 and B*0702/B*4201; and B*4201/B*4201/B*4201. Note that, while alleles B*4201 and B*4202 exhibit an extremely high degree of sequence identity, (i.e., differing only by a single non-synonymous change at nucleotide position 225: TAC and CAC, respectively) [48], it was possible to discriminate between carriers and non-carriers of either of these two alleles in the setting of all 39 other genotypes that involved addressed alleles.

Assay Validation

The assay is intended for use in discriminating carriers of the most common HLA alleles in East Africa from non-carriers. A panel of 175 specimens sampled in Kampala, Uganda, previously characterized by SBT [33], was used to assess the performance of the platform (see Table S5 for a complete list of the genotypes). Performance of the HLA-A typing system was tested on 125 samples representing 63 different genotypes, composed exclusively of addressed alleles (Table 9). Carriers and non-carriers of all 14 addressed alleles could be unequivocally discriminated, rendering genotypes that were fully concordant with those obtained by SBT. Similarly, the 141 samples whose genotypes were composed exclusively of addressed HLA-B alleles were typed with 100% sensitivity and specificity. Note that in this case the validation panel represented 83 different genotypes, combining 21/23 addressed alleles. HLA-B*2703 and B*5701 were not represented in the current panel, but the assay was able to correctly detect them in specimens from Tanzania and Kenya that had been identified as carriers of these alleles by SBT [data not shown]. Finally, 151 specimens that were exclusively carriers of the 12 addressed HLA-C alleles and that represented 59 different genotypes, were typed with this novel platform. Obtained results were fully concordant with those of SBT.

Within the validation panel, some of the specimens contained at least one allele not addressed in the current platform (Table S5). These genotypes were represented by 50, 34, and 24 samples for the HLA-A, -B, and -C loci, respectively. We proceeded to assess how the assay would perform on these samples. The obtained
results varied depending on the nature of the non-addressed alleles, and can be grouped into four main categories (Table S6). First, there were the non-addressed alleles that fully shared a reactivity pattern with addressed alleles. In this category we could mention HLA-A*0103, HLA-A*2901, HLA-A*3009, HLA-A*7403, HLA-B*1803, HLA-B*1537, HLA-Cw*0407 and HLA-Cw*0622, which, respectively, reacted exactly like the addressed alleles HLA-A*0101, HLA-A*2902, HLA-A*3002, HLA-A*7401, HLA-B*1801, HLA-B*1510, HLA-Cw*0401 and HLA-Cw*0602. These non-addressed alleles will always be typed by the platform as their cognate addressed alleles. In a second category, we included those non-addressed alleles that had a reactivity pattern closely resembling that of one of the addressed alleles, with the addition or absence of one or two reactions. For instance, non-addressed allele HLA-A*6801 shared the reactivity with A*6802 in reactions HLA-A*002, 004, and 018 but differed from the latter in having additional reactivity at reaction 017 and the absence of reactivity at 011. In the setting of most heterozygote genotypes, these minor differences in reactivity would be eclipsed by the superimposing reactivity pattern of the accompanying allele. For the most part, these non-addressed alleles could not be distinguished from the cognate addressed alleles. Other cognate pairs of addressed and non-addressed alleles falling within this category included HLA-A*2301/HLA-A*2402, HLA-A*7401/HLA-A*3201, HLA-A*3002/HLA-A*3004, HLA-B*5703/HLA-B*5702, and HLA-Cw*0602/HLA-Cw*1203. A third category included those non-addressed alleles that reacted in only one or few reactions, rendering reactivity patterns that were eclipsed by most addressed alleles. In most of these cases, samples would be genotyped as homozygous for the identified addressed allele. Examples of this category included HLA-A*3104, HLA-B*4415, HLA-Cw*0804, and HLA-Cw*1505. Finally, some non-addressed alleles had a very distinctive reactivity pattern that allowed their discrimination from cognate addressed alleles. Other cognate pairs of addressed and non-addressed alleles falling within this category included HLA-A*2301/HLA-A*2402, HLA-A*7401/HLA-A*3201, HLA-A*3002/HLA-A*3004, HLA-B*5703/HLA-B*5702, and HLA-Cw*0602/HLA-Cw*1203. A third category included those non-addressed alleles that reacted in only one or few reactions, rendering reactivity patterns that were eclipsed by most addressed alleles. In most of these cases, samples would be genotyped as homozygous for the identified addressed allele. Examples of this category included HLA-A*3104, HLA-B*4415, HLA-Cw*0804, and HLA-Cw*1505. Finally, some non-addressed alleles had a very distinctive reactivity pattern that allowed their detection in most settings. However, these variants were not included in the original design of the platform and therefore, there might be some relevant genotypic settings in which they might not be unequivocally genotyped. The main representative of this last category was HLA-A*0214.

Three main points are noteworthy about the aforementioned non-addressed alleles. They tend to be found at extremely low frequencies in reports from East African populations [32,33], and thus their exclusion from the original assay design. Secondly, the observed reactivity patterns were reproducible and consistent with those expected based on their sequence. Thirdly, in most instances the presence of a non-addressed allele was not an obstacle for the adequate genotyping of the accompanying addressed alleles. Overall, the novel genotyping platform exhibited a 100% sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) on specimens that were exclusively carriers of the 14, 23, and 12 addressed HLA-A, -B, and -C alleles, respectively. Additionally, the assay was able to correctly discriminate carriers from non-carriers of these variants even when they were part of genotypes that contained non-addressed alleles. The performance of the assay on the complete validation panel, including carriers of at least one non-addressed allele, is shown in Table S7. The sensitivity and NPV remained at 100% for all the addressed alleles. The specificity and PPV was 100% for all but 14 alleles. For the remainder, the sensitivity was 99.3–99.9% (9 alleles), 97.6–98.6% (4 alleles) and 87.1% for HLA-Cw*0701. The PPV of these alleles was 91.4–97.0% (8 alleles), 85.7–88.0% (3 alleles), and 60.0–78.3% (3 alleles). The most common interfering factor in the latter was the presence of non-addressed alleles which differed from the cognate addressed alleles by only one nucleotide base (see notes at the foot of Table S7 for details).

### Discussion

The association between genetic variation in class I HLA and the susceptibility, presentation, and outcome of infectious diseases in East Africa, and the development of preventive vaccines, are topics of high public health relevance. However, the lack of adequate tools
that can provide HLA typing information with the needed level of molecular detail, in a timely and cost-effective fashion, is one of the main obstacles to conducting large epidemiological studies. This deficiency is reflected in the very low representation of East African populations in global HLA databases [51]. Here, we presented a novel platform aimed at bridging the gap between high-throughput genotyping methods and epidemiological research.

**Table 1.** Primers and probes used in the Class I HLA-A typing platform.

| Oligonucleotides | Sequence (5′→3′)a | Locationb |
|------------------|-------------------|------------|
| **Primers**      |                   |            |
| A226F01          | GGCTCYCACTCCATGAGGTATTTTC | 203–226    |
| A228F01          | GGCTCYCACTCCATGAGGTATTTTAC | 203–228    |
| A228F02          | GGCTCYCACTCCATGAGGTATTTTCTA | 203–228    |
| A228F03          | GGCTCYCACTCCATGAGGTATTTTCTTC | 203–228    |
| A228F04          | GGCTCYCACTCCATGAGGTATTTTCTTC | 203–228    |
| A228F05          | GGCTCYCACTCCATGAGGTATTTTCTTTT | 203–228    |
| A228F06          | GGCTCYCACTCCATGAGGTATTTTCTTTT | 203–228    |
| A400R01          | TCTGTGASTGGGCCCTCACT | 400–419    |
| A400R02          | TCTGTGASTGGGCCCTCAT[A] | 400–419    |
| A400R03          | TCTGTGASTGGGCCCTCAACA | 400–419    |
| A400R04          | TCTGTGASTGGGCCCTCACA | 400–419    |
| A402R01          | TCTGTGASTGGGCCCTCTCA | 402–419    |
| A429R01          | GCAGGGTCCCCAGGTTCT | 429–446    |
| A429R02          | CCGATCTGGGAGTTCT | 429–444    |
| A429R03          | CAGGTCCTACAGGTCCG | 429–445    |
| A429R04          | CAGGTCCTACAGGTCCG | 429–445    |
| A734F01          | NGTTCTCACACCCCTCAAG | 714–734    |
| A756F01          | GTGCGCAGGTGCTCTG | 742–756    |
| A818F01          | GCAGGAGTATACGCCCC | 801–818    |
| A819F01          | GCAGGAGTATACGCC | 801–819    |
| A819F02          | GCAGGAGTATACGCC[C] | 801–819    |
| A819F03          | GCAGGAGTATACGCC[T] | 801–819    |
| A898R01          | RCTCTCMRCTGCTGCCCTC[T] | 898–916    |
| A898R02          | RCTCTCMRCTGCTGCCCTC[A] | 898–916    |
| A910F01          | TCCATCCCGGAGCAACC | 892–910    |
| A910R02          | GCCCTCCAGGGACTCTCT[C] | 910–929    |
| A910R03          | GCCCTCCAGGGACTCTCT[A] | 910–929    |
| A930R01          | GAGCCMSTCCACAGGACGT | 930–947    |
| A930R02          | GAGCCMSTCCACAGGACGT[T] | 930–947    |
| A930R03          | AGCCMSTCCACAGGACGG | 930–946    |
| A932R01          | GAGCCMSTCCACAGGACG | 932–947    |
| **Probes**       |                   |            |
| A278P01          | FAM-CGCACAAAACTGCTGCTGCC | 278–306    |
| A846P01          | TET-TCTGGAGGGGTCGCTGCTGAGG | 846–867    |
| A921P01          | TET-CTGGAGGGGTCGCTGCTGAGG | 921–944    |

aLocked-nucleic acid (LNA) bases are depicted between brackets.
bPosition relative to reference sequence NC_000006.10 30018310–30021633 (www.ncbi.nlm.nih.gov).

doi:10.1371/journal.pone.0010751.t001
| Oligonucleotides | Sequence (5′→3′) | Location |
|-----------------|-----------------|----------|
| **Primers**     |                 |          |
| B224F01         | GCTCCCACTCCATAGGTATTTTC | 202–224  |
| B225F01         | GCTCCCACTCCATAGGTATTTTC[C] | 202–225  |
| B225F02         | GCTCCCACTCCATAGGTATTTTC[G] | 202–225  |
| B225F03         | GCTCCCACTCCATAGGTATTTTC[T] | 202–225  |
| B231F01         | CCCACTCCATAGGTATTTTC[NC] | 204–231  |
| B234F01         | CCCTCCATAGGTATTTTC[AC] | 206–234  |
| B270F01         | GAGAGCCGGCTGCA[AC] | 254–270  |
| B270F02         | GAGAGCCGGCTGCA[GC] | 254–270  |
| B270F03         | GAGAGCCGGCTGCA[TC] | 254–270  |
| B270F04         | GAGAGCCGGCTGCA[TC] | 254–270  |
| B350R01         | GCCCTCTGCACTTATCA[AC] | 350–369  |
| B350R02         | GCCCTCTGCACTTATCA[GC] | 350–369  |
| B350R03         | GCCCTCTGCACTTATCA[TC] | 350–369  |
| B408R01         | GCTCTCTGGAAGTGTGTG[AT] | 408–432  |
| B429F01         | TCTCTCCTGGTGAGGCTG[CT] | 408–429  |
| B429F02         | TCTCTCCTGGTGAGGCTG[AC] | 408–429  |
| B445R01         | CGGCTCTCTGTATGAGC[CC] | 445–465  |
| B445R02         | CGGCTCTCTGTATGAGC[GC] | 445–465  |
| B445R03         | CGGCTCTCTGTATGAGC[AC] | 445–445  |
| B445R04         | CGGCTCTCTGTATGAGC[GC] | 445–468  |
| B734F01         | CAGAGCTCAGATCCACCA[AC] | 714–734  |
| B734F02         | CAGAGCTCAGATCCACCA[T] | 716–734  |
| B734F03         | CAGAGCTCAGATCCACCA[T] | 714–734  |
| B751F01         | CAGANSACTGATGGTGCCGAC | 731–751  |
| B752F01         | CAGANSACTGATGGTGCCGACC | 731–752  |
| B752F02         | CAGANSACTGATGGTGCCGAC[AC] | 731–752  |
| B752F03         | CAGANSACTGATGGTGCCGAC[GC] | 731–752  |
| B785F01         | CCTCTCTCAGGCTCCG[AT] | 769–785  |
| B785F02         | CCTCTCTCAGGCTCCG[AT] | 769–785  |
| B792F01         | CGGGGCTGATTACCACTG[AT] | 776–792  |
| B792F02         | CGGGGCTGATTACCACTG[AC] | 778–792  |
| B792F03         | CGGGGCTGATTACCACTG[GC] | 778–792  |
| B793F01         | CGGGGCTGATTACCACTG[GC] | 778–793  |
| B793F02         | CGGGGCTGATTACCACTG[AT] | 777–793  |
| B793F03         | CGGGGCTGATTACCACTG[AT] | 777–793  |
| B793F04         | CGGGGCTGATTACCACTG[AT] | 777–793  |
| B793F05         | CGGGGCTGATTACCACTG[AT] | 776–793  |
| B859R01         | GTGATCTCGACCGGCC | 859–874  |
| B859R02         | GTGATCTCGACCGGCC | 859–874  |
| B859R03         | GTGATCTCGACCGGCC | 859–874  |
| B860R01         | CTGGGATCTCGACCGGCC | 860–877  |
| B879R01         | GGGGCTGATTACCACTG[AT] | 879–894  |
| B879R02         | GGGGCTGATTACCACTG[AT] | 879–894  |
| B879R03         | GGGGCTGATTACCACTG[AT] | 879–895  |
| B911R01         | CCTCTGAGTAGTGGTCTCCTCCG | 911–933  |
| B911R02         | CCTCTGAGTAGTGGTCTCCTCCG | 911–933  |
| B911R03         | CCTCTGAGTAGTGGTCTCCTCAG | 911–933  |
| B911R04         | CCTCTGAGTAGTGGTCTCCTCCG | 911–933  |
| B932R01         | GAGCAACCTCCCACGGCAGT | 932–949  |
| B932R02         | GAGCAACCTCCCACGGCAGT | 932–949  |
| B932R03         | GAGCAACCTCCCACGGCAGT | 932–949  |
and high-resolution genotyping. When validated against a large panel of Ugandan specimens previously typed by SBT, the new assay was able to identify sensitively and unequivocally the carriers of the addressed alleles. The novel assay was successfully implemented to investigate HLA genetic diversity in Tanzania, confirming the close relationship among populations in East Africa, and revealing population-specific aspects of the genetic diversity in the studied population.

In the current platform, we implemented the 4-digit common-allele subtype resolution. In East African populations, allelic lineages tend to be represented by two or three major variants, along with several minor ones [32,33], and even minor sequence differences among alleles from the same family have been shown to lead to extremely opposite effects regarding cellular adaptive immune responses to infectious agents. One emblematic example calling for high-resolution genotyping is that of HLA-B*5801 and

| Oligonucleotides | Sequence (5′→3′)a | Locationb |
|------------------|-------------------|-----------|
| Probes B32OP01   | FAM-CWGTACGTTGGAGGGCTGACGACGACGCC-BHQ1 | 294-320   |
| B805P01          | TET-CAAGGATTACATCGGCGCTGAACGAGGCC-BHQ1 | 805-835   |

aLocked-nucleic acid (LNA) bases are depicted between brackets.  
bPosition relative to reference sequence NC_000006.10 C31432914–31429628 (www.ncbi.nlm.nih.gov).

doi:10.1371/journal.pone.0010751.t002

| Primers C235F01   | CTCCTCCAGATGATTTCTG[A] | 212–235   |
|------------------|------------------------|-----------|
| C242F01          | CCATGAGATTTCTCTACACGT  | 220–242   |
| C255F01          | TGTGCCCGGAGCA          | 242–255   |
| C255F02          | YGTGCCCGGAGCA          | 242–255   |
| C329F01          | GTTTCGACGAGCGACC       | 314–329   |
| C426R01          | GCAGGTTCACCTCGGTCAGT   | 426–444   |
| C427R01          | CGCAGGATCTCCTGAGTCAG   | 427–445   |
| C439R01          | GCAGTTCCGAGAGGT        | 439–453   |
| C439R02          | GCAGGTTCGAGAGGT[C]    | 439–453   |
| C755F01          | TACACCTCCAGGGATG       | 737–755   |
| C755F02          | TACCCTCCAGGGATGATC     | 737–755   |
| C798F01          | CCTCTCTCCAGGGTATTAG    | 783–798   |
| C799F01          | CTCCTCTCCAGGGGATTAG    | 784–799   |
| C806F01          | CCGGGGTATGACGACTA[A]  | 789–806   |
| C806F02          | CCGGGGTATGACGACTC      | 789–806   |
| C806F03          | CCGGGGTATGACGACTC[C]  | 789–806   |
| C806F04          | CCGGGGTATAGCCAGTT      | 789–806   |
| C925R01          | CTCCTCCAGGGTCTCTG      | 925–942   |
| C925R02          | CTCCTCCAGGGTCTCTCG     | 925–942   |
| C925R03          | CTCCTCCAGGGTCTCTAG     | 925–942   |
| C925R05          | CTCCTCCAGGGTCTCTAG     | 925–942   |
| C925R06          | CTCCTCCAGGGTCTCTCA     | 925–942   |
| C946R01          | AGCCACTCCACCCAGTT      | 946–962   |
| C946R02          | AGCCACTCCACCCAGCC      | 946–962   |
| C946R03          | AGCCACTCCACCCACATC     | 946–962   |
| C948R01          | GAGGGCTCCACCCAGG       | 948–963   |

aLocked-nucleic acid (LNA) bases are depicted between brackets.  
bPosition relative to reference sequence NC_000006.10 31347834–31344508 (www.ncbi.nlm.nih.gov).

doi:10.1371/journal.pone.0010751.t003

Table 3. Primers and probes used in the Class I HLA-C typing platform.

| Oligonucleotides | Sequence (5′→3′)a | Locationb |
|------------------|-------------------|-----------|
| Probes C380P01   | FAM-CGCGGTATTCTGCTGCTCTCCAGGAGCGTTTCA-TACTCC-BHQ1 | 380–415   |
| C818P01          | TET-ACAGGGATTAGCTGAGGCAATCTTCAG-TGTTC-BHQ1 | 818–848   |

Table 2. Cont.
B*5802, which differs in only 3/1089 exonic nucleotide bases, and are associated in vivo with control of HIV replication and ineffective cellular immune responses, respectively [31]. While there are precedents for the use of real-time PCR for class I HLA genotyping [52,53], those assays usually gave only two-digit level (i.e., allelic-group designation) typing resolution, and therefore were not adequate for immunoepidemiological studies in East African populations.

HLA loci have evolved through mutation as well as recombination [54]; thus HLA alleles cannot be defined by a single nucleotide polymorphism (SNP) but rather by an array of cis-linked SNPs. Breaking the cis-linkage among SNPs is one of the main drawbacks of some HLA typing methods (e.g., SBT) as it can hamper the typing of heterozygous individuals [43]. By basing the novel platform on the PCR-SSP method, we were able to preserve both the information about the polymorphisms and their linkage. To avoid time-consuming post-PCR detection by agarose-gel electrophoresis, which is one of the main disadvantages of conventional PCR-SSP, we opted to implement the platform using real-time PCR, where the detection of the positive reactivity is concurrent with the amplification reaction itself, in a closed system [47]. Furthermore, performing real-time PCR-SSP in a multiplex format allowed the incorporation of internal standardization, measuring in parallel the degree of sequence identity between template and primers, and the amount of template incorporated in the reaction. Due to the reaction conditions used in the real-time PCR-SSP, only amplicons shorter than 250 bp could be efficiently amplified. For this reason, only the linkage between SNPs lying in the same exon could be interrogated. Nevertheless, the information provided by these reactions was suitable for the intended use of the assay.

The high throughput, low cost, low post-PCR processing, and automation potential that characterize real-time PCR present clear advantages over other widely used techniques, such as conventional PCR-SSP or PCR-SSOP. Despite the high initial setup cost of the infrastructure required to run real-time PCR, equipment and reagents are progressively becoming standard tools in molecular biology, especially in laboratories dedicated to genetics of infectious and autoimmune diseases, or can be found in genotyping core facilities. It is likely that the evolution of real-time PCR technologies will soon allow for implementing the current platform closer to the field, where the data is being collected [55,56]. The interpretation of the results can be computerized by direct export of Ct values from the instrument, followed by their conversion into reactive/non-reactive binary patterns and comparison to expected reactivity patterns for addressed genotypes, and finally, the assembly into a database. The minimal need for manual data entry makes the current

| Table 4. Primer and probe combinations Class HLA-A typing reactions by real-time PCR. |
|-----------------|-----------------|-----------------|
| Master Mix     | Specific reaction | Internal standard reaction |
|                | Primers\(^a\) | Primers | Probe | Probe | Specificity\(^b\) |
|                | Forward | Reverse | Forward | Reverse |         |         |         |
| HLA-A 001      | A228F01 | A429R03 | A278P01 | A818F01 | A932R01 | A846P01 | A*2902 |
| HLA-A 002      | A228F02 | A429R04 | A278P01 | A818F01 | A932R01 | A846P01 | A*0205, A*3402, A*6601, A*6802 |
| HLA-A 003      | A228F02 | A400R01 | A278P01 | A818F01 | A932R01 | A846P01 | A*0205 |
| HLA-A 004      | A228F02 | A400R03 | A278P01 | A818F01 | A932R01 | A846P01 | A*3402, A*6601, A*6802 |
| HLA-A 005      | A228F04 | A429R02 | A278P01 | A818F01 | A932R01 | A846P01 | A*2301 |
| HLA-A 006      | A228F03 | A429R01 | A278P01 | A818F01 | A932R01 | A846P01 | A*3002 |
| HLA-A 007      | A228F05 | A400R02 | A278P01 | A818F01 | A932R01 | A846P01 | A*0101, A*3601 |
| HLA-A 008      | A228F06 | A400R01 | A278P01 | A818F01 | A932R01 | A846P01 | A*0201, A*0202 |
| HLA-A 009      | A228F06 | A400R04 | A278P01 | A818F01 | A932R01 | A846P01 | A*0301, A*7401 |
| HLA-A 010      | A228F06 | A429R04 | A278P01 | A818F01 | A932R01 | A846P01 | A*0201, A*0202, A*0301, A*7401 |
| HLA-A 011      | A734F01 | A898R02 | A846P01 | A226F01 | A402R01 | A278P01 | A*0201, A*0202, A*0205, A*6802 |
| HLA-A 012      | A819F02 | A930R03 | A846P01 | A226F01 | A402R01 | A278P01 | A*0101, A*6601 |
| HLA-A 013      | A819F03 | A930R01 | A846P01 | A226F01 | A402R01 | A278P01 | A*2902, A*7401 |
| HLA-A 014      | A910F01 | A930R02 | A921F01 | A226F01 | A402R01 | A278P01 | A*3601 |
| HLA-A 015      | A756F01 | A898R01 | A846P01 | A226F01 | A402R01 | A278P01 | A*0301, A*3402 |
| HLA-A 016      | A819F02 | A910R03 | A846P01 | A226F01 | A402R01 | A278P01 | A*0201, A*0301, A*2301, A*3001, A*3002, A*3402 |
| HLA-A 017      | A756F01 | A910R02 | A846P01 | A226F01 | A402R01 | A278P01 | A*0202, A*0205 |
| HLA-A 018      | A819F04 | A910R02 | A846P01 | A226F01 | A402R01 | A278P01 | A*0101, A*0202, A*0205, A*3601, A*6601, A*6802 |
| HLA-A 019      | A228F04 | A429R04 | A278P01 | A818F01 | A932R01 | A846P01 | A*3001 |
| HLA-A 020      | A228F04 | A400R04 | A278P01 | A818F01 | A932R01 | A846P01 | A*3001, A*3002 |

\(^a\)Primer and probes names refer to Table 1.
\(^b\)Only addressed alleles are indicated.
Table 5. Primer and probe combinations Class HLA-B typing reactions by real-time PCR.

| Master Mix | Specific reaction | Internal standard reaction | Specificityb |
|------------|-------------------|----------------------------|--------------|
|            | Primsa            | Primes                      |              |
|            | Forward | Reverse | Probe | Forward | Reverse | Probe |              |
| HLA-B 001  | B225F01          | B350R01                     | B320P01      | B751F01 | B860R01 | B805P01 | B*4101, B*4501, B*4901 |
| HLA-B 002  | B225F01          | B408R01                     | B320P01      | B751F01 | B860R01 | B805P01 | B*1801, B*4101, B*4501, B*4901 |
| HLA-B 003  | B225F02          | B350R02                     | B320P01      | B751F01 | B860R01 | B805P01 | B*0801 |
| HLA-B 004  | B225F03          | B429F01                     | B320P01      | B751F01 | B860R01 | B805P01 | B*0702, B*4201, B*8101 |
| HLA-B 005  | B231F01          | B429F02                     | B320P01      | B751F01 | B860R01 | B805P01 | B*1516, B*5701, B*5703, B*5801, B*5802 |
| HLA-B 006  | B231F01          | B445R02                     | B320P01      | B751F01 | B860R01 | B805P01 | B*0801, B*1402, B*1503, B*1510, B*3501, B*4101, B*4501 |
| HLA-B 007  | B231F01          | B445R04                     | B320P01      | B751F01 | B860R01 | B805P01 | B*1302, B*1516, B*4403, B*4901, B*5101, B*5301, B*5701, B*5703, B*5801, B*5802 |
| HLA-B 008  | B234F01          | B445R02                     | B320P01      | B751F01 | B860R01 | B805P01 | B*0801, B*1503, B*1510, B*3501, B*4101, B*4501 |
| HLA-B 009  | B270F01          | B408R01                     | B320P01      | B751F01 | B860R01 | B805P01 | B*1302, B*4101, B*4403, B*4501, B*4901 |
| HLA-B 010  | B270F01          | B445R01                     | B320P01      | B751F01 | B860R01 | B805P01 | B*4101, B*4501 |
| HLA-B 011  | B270F01          | B445R04                     | B320P01      | B751F01 | B860R01 | B805P01 | B*1302, B*2703, B*4403, B*4901 |
| HLA-B 012  | B270F02          | B350R01                     | B320P01      | B751F01 | B860R01 | B805P01 | B*1516, B*3501, B*5301, B*5701, B*5703, B*5801, B*5802 |
| HLA-B 013  | B270F02          | B408R01                     | B320P01      | B751F01 | B860R01 | B805P01 | B*3501, B*5301 |
| HLA-B 014  | B270F02          | B445R02                     | B320P01      | B751F01 | B860R01 | B805P01 | B*3501 |
| HLA-B 015  | B270F03          | B429F01                     | B320P01      | B751F01 | B860R01 | B805P01 | B*0702, B*4201, B*4403, B*4901 |
| HLA-B 016  | B270F03          | B445R02                     | B320P01      | B751F01 | B860R01 | B805P01 | B*0702, B*0801, B*1402, B*1503, B*1510, B*1801, B*4201, B*4901 |
| HLA-B 017  | B270F04          | B445R04                     | B320P01      | B751F01 | B860R01 | B805P01 | B*5101 |
| HLA-B 018  | B734F01          | B859R01                     | B805P01      | B224F01 | B445R03 | B320P01 | B*5802 |
| HLA-B 019  | B734F02          | B932R02                     | B805P01      | B224F01 | B445R03 | B320P01 | B*5802 |
| HLA-B 020  | B734F03          | B911R02                     | B805P01      | B224F01 | B445R03 | B320P01 | B*1402, B*5802 |
| HLA-B 021  | B752F01          | B879R02                     | B805P01      | B224F01 | B445R03 | B320P01 | B*1516, B*3501, B*4501, B*4901, B*5301, B*5501, B*5801, B*5802 |
| HLA-B 022  | B752F02          | B859R01                     | B805P01      | B224F01 | B445R03 | B320P01 | B*1302, B*3501, B*4501, B*4901, B*5101, B*5301, B*5801, B*5802 |
| HLA-B 023  | B752F02          | B932R03                     | B805P01      | B224F01 | B445R03 | B320P01 | B*4501 |
| HLA-B 024  | B752F03          | B859R02                     | B805P01      | B224F01 | B445R03 | B320P01 | B*0702, B*1503, B*1510, B*2703, B*5701, B*5703, B*8101 |
| HLA-B 025  | B752F03          | B879R01                     | B805P01      | B224F01 | B445R03 | B320P01 | B*0702, B*0801, B*1402, B*1503, B*1510, B*1801, B*2703, B*4101, B*4201, B*4403, B*5101, B*5701, B*5703, B*8101 |
| HLA-B 026  | B752F03          | B932R03                     | B805P01      | B224F01 | B445R03 | B320P01 | B*1503, B*1510, B*4403, B*5101, B*5701, B*5703 |
| HLA-B 027  | B785F01          | B879R01                     | B805P01      | B224F01 | B445R03 | B320P01 | B*0801, B*4101, B*4201, B*4403, B*5101, B*5701, B*5703, B*8101 |
molecular platform ideal for epidemiologic studies. In our hands, a single operator with a fully dedicated instrument can genotype class I HLA-A, -B, and -C for ca. 50 specimens per week. Achieving a comparable throughput by conventional PCR-based techniques would require a much larger work force, dedicated to labor-intensive gel electrophoresis, interpretation, and manual data entry.

The current platform has several limitations inherent to its design, so it is not meant to replace gold-standard SBT, and it should be used only for research and not for diagnostics or therapeutics purposes. With the current assay, only addressed alleles can be detected with high sensitivity and specificity. Rare, non-addressed alleles sometimes cannot be detected, leading to overcalling of homozygotes. Assessing major deviations from Hardy-Weinberg equilibrium can help identify this problem. Alternatively, non-addressed variants may be assigned to highly related addressed alleles, and SBT may be used for further genotype confirmation.

The extreme level of genetic diversity characteristic of the HLA loci prevents the achievement of high-sensitivity and high-specificity typing of the over 2,000 class I HLA-A, -B, and -C alleles reported worldwide. However, our focusing on the 49 most common variants reported in East Africa, which provide 80–90% population coverage, offered an adequate balance between the quantity and the quality of the data that can be gathered. While many alleles found in East Africa were not addressed in the current assay, their very low representation in these populations results in their relatively low public health impact. The modular and “open source” nature of the current assay permits incorporation, by any member of the field, of further reactions that can allow for the discrimination of carriers of any given non-addressed variant deemed to be of interest. The current molecular platform was tailor-made for East Africa, and thus has an application limited only to this geographic area, which is home to more than 100 million individuals and presents high prevalence of infectious diseases including HIV/AIDS, malaria, and tuberculosis.

| Master Mix | Specific reaction | Internal standard reaction | Specificity<sup>b</sup> |
|------------|-------------------|---------------------------|-------------------------|
|             | Primers<sup>a</sup> | Primers | Probe | Primes | Probe | |
|             | Forward | Reverse | Forward | Reverse | B224F01 | B44SR03 | B320P01 | B*1302, B*5101, B*5703, B*8101 |
| HLA-B 028   | B785F01 | B911R02 | B805P01 | B224F01 | B44SR03 | B320P01 | B*1302, B*5101, B*5703, B*8101 |
| HLA-B 029   | B785F01 | B932R03 | B805P01 | B224F01 | B44SR03 | B320P01 | B*5101, B*5703 |
| HLA-B 030   | B785F02 | B879R01 | B805P01 | B224F01 | B44SR03 | B320P01 | B*0702, B*1503, B*1510, B*1516, B*1801, B*3501, B*5301, B*5701, B*5801, B*5802 |
| HLA-B 031   | B785F02 | B911R02 | B805P01 | B224F01 | B44SR03 | B320P01 | B*1503, B*1510, B*1516, B*1801, B*3501, B*5301, B*5701, B*5801, B*5802 |
| HLA-B 032   | B785F02 | B932R03 | B805P01 | B224F01 | B44SR03 | B320P01 | B*4403 |
| HLA-B 033   | B793F01 | B859R01 | B805P01 | B224F01 | B44SR03 | B320P01 | B*2703, B*4403 |
| HLA-B 034   | B793F01 | B879R02 | B805P01 | B224F01 | B44SR03 | B320P01 | B*2703, B*4403 |
| HLA-B 035   | B793F01 | B911R03 | B805P01 | B224F01 | B44SR03 | B320P01 | B*2703, B*4403 |
| HLA-B 036   | B792F01 | B911R02 | B805P01 | B224F01 | B44SR03 | B320P01 | B*1503, B*5101, B*5703, B*8101 |
| HLA-B 037   | B792F01 | B911R04 | B805P01 | B224F01 | B44SR03 | B320P01 | B*0801, B*4101, B*4201, B*4202 |
| HLA-B 038   | B792F01 | B932R02 | B805P01 | B224F01 | B44SR03 | B320P01 | B*1510, B*5101, B*5703 |
| HLA-B 039   | B793F02 | B911R01 | B805P01 | B224F01 | B44SR03 | B320P01 | B*0702 |
| HLA-B 040   | B792F02 | B911R02 | B805P01 | B224F01 | B44SR03 | B320P01 | B*1503, B*1516, B*1801, B*3501, B*5301, B*5701, B*5801, B*5802 |
| HLA-B 041   | B792F02 | B932R02 | B805P01 | B224F01 | B44SR03 | B320P01 | B*1503, B*1516, B*1801, B*3501, B*5301, B*5701, B*5801, B*5802 |
| HLA-B 042   | B792F03 | B859R02 | B805P01 | B224F01 | B44SR03 | B320P01 | B*1503, B*1516, B*1801, B*3501, B*5301, B*5701, B*5801, B*5802 |
| HLA-B 043   | B793F03 | B879R03 | B805P01 | B224F01 | B44SR03 | B320P01 | B*1503, B*1516, B*1801, B*3501, B*5301, B*5701, B*5801, B*5802 |
| HLA-B 044   | B793F04 | B911R02 | B805P01 | B224F01 | B44SR03 | B320P01 | B*1402 |
| HLA-B 045   | B793F05 | B932R01 | B805P01 | B224F01 | B44SR03 | B320P01 | B*1402 |
| HLA-B 046   | B752F02 | B859R03 | B805P01 | B224F01 | B44SR03 | B320P01 | B*1516 |

*a* primer and probes names refer to Table 2.  
*b* Only addressed alleles are indicated.  
doi:10.1371/journal.pone.0010751.t005  

Table 5. Cont.
### Table 6. Primer and probe combinations Class HLA-C typing reactions by real-time PCR.

| Master Mix | Specific reaction | Internal standard reaction | Specificity<sup>b</sup> |
|------------|-------------------|----------------------------|-------------------------|
|            | Primers<sup>a</sup> | Primers | Probe | Primes | Probe | Forward | Reverse | Forward | Reverse | Cw*0602, Cw*1801 |
| HLA-C 001  | C235F01 C439R01 C380P01 | C798F01 C948R01 C818P01 | Cw*0602, Cw*1801 |
| HLA-C 002  | C235F01 C439R02 C380P01 | C798F01 C948R01 C818P01 | Cw*0701, Cw*0702, Cw*0704 |
| HLA-C 003  | C242F01 C439R01 C380P01 | C798F01 C948R01 C818P01 | Cw*0401 |
| HLA-C 004  | C255F02 C439R02 C380P01 | C798F01 C948R01 C818P01 | Cw*0302, Cw*0304, Cw*0701, Cw*0702, Cw*0704, Cw*0802, Cw*1601 |
| HLA-C 005  | C806F02 C925R06 C818P01 | C329F01 C427R01 C380P01 | Cw*0210, Cw*0602 |
| HLA-C 006  | C806F03 C946R01 C818P01 | C329F01 C427R01 C380P01 | Cw*0602, Cw*0701, Cw*0702, Cw*1601 |
| HLA-C 007  | C806F04 C946R03 C818P01 | C329F01 C427R01 C380P01 | Cw*1701 |
| HLA-C 008  | C806F01 C946R02 C818P01 | C329F01 C427R01 C380P01 | Cw*0304 |
| HLA-C 009  | C799F01 C925R05 C818P01 | C329F01 C427R01 C380P01 | Cw*0704 |
| HLA-C 010  | C755F02 C925R03 C818P01 | C329F01 C427R01 C380P01 | Cw*0702 |
| HLA-C 011  | C799F01 C925R01 C818P01 | C329F01 C427R01 C380P01 | Cw*1601 |
| HLA-C 012  | C806F04 C925R02 C818P01 | C329F01 C427R01 C380P01 | Cw*0401, Cw*0802, Cw*1801 |
| HLA-C 013  | C255F01 C426R01 C380P01 | C798F01 C948R01 C818P01 | Cw*0210 |
| HLA-C 014  | C806F03 C946R02 C818P01 | C329F01 C427R01 C380P01 | Cw*0302 |
| HLA-C 015  | C755F01 C925R03 C818P01 | C329F01 C427R01 C380P01 | Cw*0302, Cw*0304, Cw*0701, Cw*1701 |

<sup>a</sup>Primer and probes names refer to Table 3.
<sup>b</sup>Only addressed alleles are indicated.

doi:10.1371/journal.pone.0010751.t006

### Table 7. Reactivity patterns for HLA-A addressed alleles.

| Reaction | HLA-A Allele |
|----------|--------------|
|          | A*0101 | A*0201 | A*0202 | A*0205 | A*0301 | A*2301 | A*2902 | A*3001 | A*3002 | A*3402 | A*3601 | A*6601 | A*6802 | A*7401 |
| HLA-A 001 | X |
| HLA-A 002 | X | X | X | X | X |
| HLA-A 003 | X |
| HLA-A 004 | X | X | X |
| HLA-A 005 | X |
| HLA-A 006 | X |
| HLA-A 007 | X | X |
| HLA-A 008 | X | X |
| HLA-A 009 | X | X |
| HLA-A 010 | X | X | X | X |
| HLA-A 011 | X | X | X |
| HLA-A 012 | X | X |
| HLA-A 013 | X | X |
| HLA-A 014 | X |
| HLA-A 015 | X | X |
| HLA-A 016 | X | X | X | X | X |
| HLA-A 017 | X | X |
| HLA-A 018 | X | X | X | X | X |
| HLA-A 019 | X |
| HLA-A 020 | X | X |

doi:10.1371/journal.pone.0010751.t007
Similar platforms based on the same principles, targeting the HLA genetic diversity in other global populations (e.g., Southeast Asia), are currently being designed to support large cohort-based studies.

Using the novel typing platform, we were able to provide for the first time a detailed description of a Tanzanian population. Genetic distance analyses demonstrate that this population was highly related to other sub-Saharan groups, and more specifically, it was embedded within the previously defined major East African cluster [32,33]. These results are concordant with recently published findings, based on the analysis of non-immunogenetic loci [57]. The commonalities found between the Tanzanian, Ugandan and Kenyan populations were reflected in the presence of the same allelic lineages, defining the immunogenetic background of East African populations. On the other hand, subtle genetic differences among these groups were also evident, indicating the uniqueness of each individual population within the major cluster. Interestingly, each of these populations is home to unique genetic forms of common widely spread pathogens. For instance, HIV type-1 strains circulating in East Africa represent mostly group-M subtypes A, C, D, and a constellation of recombinant forms among them, but the genetic subtypes are differently balanced in each country [58,59,60,61,62]. Coupled with existing high-throughput viral subtyping assays [62], the current platform will be able to provide high-resolution HLA information with the needed throughput, to elucidate the underlying immunogenetic basis of this unique subtype distribution.

Among the most relevant immunoepidemiological applications for the novel genotyping platform are association studies between host genotype and disease susceptibility and outcome [31], and the analysis of host-pathogen genetic co-variation [63,64]. Furthermore, this assay allows for the identification of large numbers of individuals who are carriers of HLA alleles of interest to support functional characterization of immune responses to pathogens [65] or vaccines [66]. High-resolution HLA typing has provided deep insight into the underlying molecular mechanisms of host-pathogen interaction [67]. East Africa is one of the world regions with the highest pathogen burdens [14], which can be mitigated by preventive vaccines. The availability of high-throughput high-resolution HLA typing platforms, such as the one presented here, will be extremely useful in the identification of correlates of immune protection and the evaluation of the effectiveness of candidate vaccines.

### Materials and Methods

#### Ethics Statement

All volunteers completed informed consent, and the study was reviewed and approved by the human subject ethics and safety committees, in compliance with all relevant federal guidelines and institutional policies.

#### Sequence alignment for assay development

Published class I HLA-A, -B, and -C nucleotide sequences of alleles reported in East Africa [32,33] were retrieved from the IMGT/HLA Database (http://www.ebi.ac.uk/imgt/hla/) [68]. For each locus, alignments of nucleotide sequences representing the targeted alleles were constructed using ClustalX [69] and were manually edited using Genetic Data Environment [70]. Polymorphic sites that helped to discriminate among these alleles were identified by visual inspection. The sequence analysis was restricted to exons 2 and 3 of the HLA loci, which define the peptide-binding α1 and α2 domains, the only region for which sequences were available for all of the targeted alleles defined at the 4-digit level.

#### Primer/Probe Design

Oligonucleotide primers and probes were designed using Primer Express software version 2.0 (Applied Biosystems, Foster City, CA) and PrimerSelect version 7.1.0 as implemented in the Lasergene package (DNASTAR, Madison, WI). The primers were designed so that their 3’extremes would determine their sequence specificity, their melting temperature (Tm) would be approximately 65°C to ensure uniform amplification conditions, and with

---

**Table 8. Reactivity patterns for HLA-C addressed alleles.**

| Reaction | HLA-C Allele |
|----------|--------------|
|          | Cw*0210 | Cw*0302 | Cw*0304 | Cw*0401 | Cw*0602 | Cw*0701 | Cw*0702 | Cw*0704 | Cw*0802 | Cw*1601 | Cw*1701 | Cw*1801 |
| HLA-C 001 | X | X | X | X | X | X | X | X | X | X | X | X |
| HLA-C 002 | X | X | X | X | X | X | X | X | X | X | X | X |
| HLA-C 003 | X | X | X | X | X | X | X | X | X | X | X | X |
| HLA-C 004 | X | X | X | X | X | X | X | X | X | X | X | X |
| HLA-C 005 | X | X | X | X | X | X | X | X | X | X | X | X |
| HLA-C 006 | X | X | X | X | X | X | X | X | X | X | X | X |
| HLA-C 007 | X | X | X | X | X | X | X | X | X | X | X | X |
| HLA-C 008 | X | X | X | X | X | X | X | X | X | X | X | X |
| HLA-C 009 | X | X | X | X | X | X | X | X | X | X | X | X |
| HLA-C 010 | X | X | X | X | X | X | X | X | X | X | X | X |
| HLA-C 011 | X | X | X | X | X | X | X | X | X | X | X | X |
| HLA-C 012 | X | X | X | X | X | X | X | X | X | X | X | X |
| HLA-C 013 | X | X | X | X | X | X | X | X | X | X | X | X |
| HLA-C 014 | X | X | X | X | X | X | X | X | X | X | X | X |
| HLA-C 015 | X | X | X | X | X | X | X | X | X | X | X | X |

[doi:10.1371/journal.pone.0010751.t008](http://www.plosone.org)
### Table 9. Performance of typing platform on validation panel.

| Class I HLA Allele | Individuals bearing the allele(n)* | Performance |
|--------------------|------------------------------------|-------------|
|                    |                                    | Sensitivity | Specificity | Positive predictive value | Negative predictive value |
| A*0101             | 19                                 | 100.0%      | 100.0%      | 100.0%                    | 100.0%                    |
| A*0201             | 35                                 | 100.0%      | 100.0%      | 100.0%                    | 100.0%                    |
| A*0202             | 13                                 | 100.0%      | 100.0%      | 100.0%                    | 100.0%                    |
| A*0205             | 4                                  | 100.0%      | 100.0%      | 100.0%                    | 100.0%                    |
| A*0301             | 13                                 | 100.0%      | 100.0%      | 100.0%                    | 100.0%                    |
| A*2301             | 23                                 | 100.0%      | 100.0%      | 100.0%                    | 100.0%                    |
| A*2902             | 13                                 | 100.0%      | 100.0%      | 100.0%                    | 100.0%                    |
| A*3001             | 17                                 | 100.0%      | 100.0%      | 100.0%                    | 100.0%                    |
| A*3002             | 27                                 | 100.0%      | 100.0%      | 100.0%                    | 100.0%                    |
| A*3402             | 4                                  | 100.0%      | 100.0%      | 100.0%                    | 100.0%                    |
| A*3601             | 9                                  | 100.0%      | 100.0%      | 100.0%                    | 100.0%                    |
| A*5601             | 18                                 | 100.0%      | 100.0%      | 100.0%                    | 100.0%                    |
| A*6802             | 17                                 | 100.0%      | 100.0%      | 100.0%                    | 100.0%                    |
| A*7401             | 31                                 | 100.0%      | 100.0%      | 100.0%                    | 100.0%                    |
| B*0702             | 13                                 | 100.0%      | 100.0%      | 100.0%                    | 100.0%                    |
| B*0801             | 12                                 | 100.0%      | 100.0%      | 100.0%                    | 100.0%                    |
| B*1302             | 4                                  | 100.0%      | 100.0%      | 100.0%                    | 100.0%                    |
| B*1402             | 10                                 | 100.0%      | 100.0%      | 100.0%                    | 100.0%                    |
| B*1503             | 25                                 | 100.0%      | 100.0%      | 100.0%                    | 100.0%                    |
| B*1510             | 15                                 | 100.0%      | 100.0%      | 100.0%                    | 100.0%                    |
| B*1516             | 1                                  | 100.0%      | 100.0%      | 100.0%                    | 100.0%                    |
| B*1801             | 5                                  | 100.0%      | 100.0%      | 100.0%                    | 100.0%                    |
| B*3501             | 4                                  | 100.0%      | 100.0%      | 100.0%                    | 100.0%                    |
| B*4101             | 3                                  | 100.0%      | 100.0%      | 100.0%                    | 100.0%                    |
| B*4201             | 21                                 | 100.0%      | 100.0%      | 100.0%                    | 100.0%                    |
| B*4202             | 1                                  | 100.0%      | 100.0%      | 100.0%                    | 100.0%                    |
| B*4403             | 1                                  | 100.0%      | 100.0%      | 100.0%                    | 100.0%                    |
| B*4501             | 32                                 | 100.0%      | 100.0%      | 100.0%                    | 100.0%                    |
| B*4901             | 14                                 | 100.0%      | 100.0%      | 100.0%                    | 100.0%                    |
| B*5101             | 3                                  | 100.0%      | 100.0%      | 100.0%                    | 100.0%                    |
| B*5301             | 34                                 | 100.0%      | 100.0%      | 100.0%                    | 100.0%                    |
| B*5703             | 9                                  | 100.0%      | 100.0%      | 100.0%                    | 100.0%                    |
| B*5801             | 19                                 | 100.0%      | 100.0%      | 100.0%                    | 100.0%                    |
| B*5802             | 29                                 | 100.0%      | 100.0%      | 100.0%                    | 100.0%                    |
| B*8101             | 14                                 | 100.0%      | 100.0%      | 100.0%                    | 100.0%                    |
| Cw*0210            | 26                                 | 100.0%      | 100.0%      | 100.0%                    | 100.0%                    |
| Cw*0302            | 9                                  | 100.0%      | 100.0%      | 100.0%                    | 100.0%                    |
| Cw*0304            | 21                                 | 100.0%      | 100.0%      | 100.0%                    | 100.0%                    |
| Cw*0401            | 47                                 | 100.0%      | 100.0%      | 100.0%                    | 100.0%                    |
| Cw*0602            | 55                                 | 100.0%      | 100.0%      | 100.0%                    | 100.0%                    |
| Cw*0701            | 46                                 | 100.0%      | 100.0%      | 100.0%                    | 100.0%                    |
| Cw*0702            | 11                                 | 100.0%      | 100.0%      | 100.0%                    | 100.0%                    |
| Cw*0704            | 6                                  | 100.0%      | 100.0%      | 100.0%                    | 100.0%                    |
| Cw*0802            | 13                                 | 100.0%      | 100.0%      | 100.0%                    | 100.0%                    |
| Cw*1601            | 15                                 | 100.0%      | 100.0%      | 100.0%                    | 100.0%                    |
| Cw*1701            | 23                                 | 100.0%      | 100.0%      | 100.0%                    | 100.0%                    |
| Cw*1801            | 10                                 | 100.0%      | 100.0%      | 100.0%                    | 100.0%                    |

*Only samples from individuals bearing fully-addressed genotypes at the corresponding locus are reported (HLA-A: n = 125; HLA-B: n = 141; HLA-C: n = 151).

doi:10.1371/journal.pone.0010751.t009
Real-time PCR-SSP

For HLA typing, 900–980 bp fragments encompassing exons 2 through 3 of HLA-A, -B, or -C were PCR amplified in three separate reactions using locus-specific primers targeting conserved regions of each respective HLA gene, as previously described [46,47]. Briefly, the first-round PCR contained 10× PCR Gold Buffer (Applied Biosystems, Foster City, CA), 200 nM of each primer (Sigma Aldrich, St. Louis, MO) [46], 1.25 U of AmpliTaq Gold DNA Polymerase (Applied Biosystems, Foster City, CA) and genomic DNA (20–100 ng) in a final volume of 50 μL. Thermocycling conditions were: 10 min at 95°C, followed by 30 cycles of 30 seconds at 95°C, 1 minute at 65°C, and 2 minutes at 72°C. First-round PCR products were each diluted 1000-fold in molecular-grade water for use in subsequent real-time PCR-based genotyping reactions. Corresponding first-round PCR dilutions were distributed into 20, 46 and 15 separate real-time-PCR-SSPs for the targeted variants in HLA-A, -B, and -C, respectively. Each reaction used a multiplex format designed to target both a sequence-specific region and a non-polymorphic region of the amplicon itself, for internal standardization. Amplification was monitored in real-time using TaqMan fluorescent probes. When variation was assessed in the exon 2 using polymorphism-specific primers and FAM-labeled probes, the internal standardization reaction was designed to amplify a segment of exon 3 with detection by TET-labeled probes, and vice versa for exon 3. Tables 1, Table 2, Table 3, Table 4, Table 5 and Table 6 indicate the sequences and combinations of primers and probes used for each of the typing reactions. Several primers contain locked nucleic acid (LNA) modifications at the 3’ extreme [71,72]. Because LNAs are a class of nucleic acid analogues that have a more rigid configuration than standard oligonucleotide primers, they perform with higher specificity than standard primers, although sometimes at the expense of amplification efficiency [47]. The applicability of LNAs for each reaction was determined empirically (data not shown). Each of the genotyping real-time PCR mixtures consisted of TaqMan 2× Universal PCR Master Mix No AmpErase UNG (Applied Biosystems, Foster City, CA), 400 nM of each forward and reverse sequence-specific primers (Sigma Aldrich, St. Louis, MO and Exiqon, Vedbaek, Denmark), 400 nM of each forward and reverse universal primers (Sigma Aldrich, St. Louis, MO), 250 nM of a locus-specific probe (Sigma Aldrich, St. Louis, MO), 250 nM of an internal-standardization probe (Sigma Aldrich, St. Louis, MO), and diluted first-round PCR product, in a final volume of 6.25 μL. Samples were run in a 384-well plate format with the following thermocycling program: 10 min at 95°C followed by 60 cycles of 15 seconds at 95°C and 1 minute at 60°C. The intensity of each fluorescent probe was read automatically by the 7900HT Fast Real-time PCR System (Applied Biosystems, Foster City, CA) then analyzed and interpreted with Sequence Detection Software version 2.2.2 (Applied Biosystems, Foster City, CA) as the cycle threshold (Ct), i.e., the number of cycles required to bring the fluorescent signal generated in the reaction above a set threshold. Samples that did not cross the threshold were manually assigned a Ct of the maximum 60. In all cases, non-template controls were included where water substituted for genomic DNA. Positive reactivity for each reaction was determined by computation of the difference in Ct values between the sequence-specific and the internal-standardization reactions and comparison to empirically determined cut-offs. The calling of HLA genotypes was performed by comparing the observed aggregate reactivity patterns of real-time PCR-SSP with those deduced from the sequences of addressed alleles (Table 7, Table 8, Table S1, Table S2, Table S3, and Table S4).

Assay validation

Assay validation was based on a panel of 175 specimens from Kampala, Uganda, previously characterized by class I HLA-A, -B, and -C alleles and the Serologic Malaria Workshop (SMW) at the 4-digit level [33]. Genomic DNA was extracted from Epstein-Barr virus (EBV) transformed B-cell lines prepared from peripheral blood mononuclear cells (PBMCs) separated from whole blood (MagNA pure total nucleic acid extraction, Roche Diagnostics Corp., Indianapolis, IN). Detailed previous analysis had demonstrated that these specimens provided a representative sample of the HLA genetic diversity found in East Africa [33]. The assay was validated on the panel of 175 specimens from Uganda, previously characterized by class I HLA-A, -B, and -C alleles and the Serologic Malaria Workshop (SMW) at the 4-digit level [33]. Genomic DNA was extracted from Epstein-Barr virus (EBV) transformed B-cell lines prepared from peripheral blood mononuclear cells (PBMCs) separated from whole blood (MagNA pure total nucleic acid extraction, Roche Diagnostics Corp., Indianapolis, IN).
Comparison of genetic composition among world populations

Class I HLA-A, -B, and -C allele frequencies from world populations were retrieved from the dbMHC database [75]. To facilitate the comparison between the current SBT HLA data with historical datasets, which were often described using other techniques or with other levels of molecular resolution, allele Cw*0210 was considered synonymous with Cw*0202 [76]. Similarly, for HLA-C alleles that are often not distinguishable, the previously defined allele grouping systems were applied, which include Cw*0401G, Cw*0501G, Cw*0701G, Cw*0704G, Cw*1701G, and Cw*1801G [32]. Inter-population genetic distances were estimated using the definition proposed by Cavalli-Sforza and Bodmer [49,50], which is a measure of the level of overlap of genetic variants between pairs of populations, as implemented by the GENDIST module of PHYLIP (Phylogeny Inference Package) version 3.6 [77]. The estimated genetic distance matrices so obtained were used to construct unrooted dendrograms through the neighbor-joining algorithm [78] as implemented in MEGA version 4 [79]. Contingency tables were tested using the Fisher’s exact test and the Fisher-Freeman-Halton test using StatXact Version 6 (Cytel Software Corporation, MA).

Principal component analysis (PCA) was performed using JMP®, Version 7.0.2 (SAS Institute Inc., Cary, NC) based on the calculated genetic distances.

Supporting Information

Table S1 Reactivity patterns for HLA-B addressed alleles.  
Found at: doi:10.1371/journal.pone.0010751.s001 (0.03 MB XLS)

Table S2 Expected reactivity patterns for 105 HLA-A genotypes among addressed alleles.  
Found at: doi:10.1371/journal.pone.0010751.s002 (0.05 MB XLS)

Table S3 Expected reactivity patterns for 276 HLA-B genotypes among addressed alleles.  
Found at: doi:10.1371/journal.pone.0010751.s003 (0.21 MB XLS)

Table S4 Expected reactivity patterns for 78 HLA-C genotypes among addressed alleles.  
Found at: doi:10.1371/journal.pone.0010751.s004 (0.04 MB XLS)

Table S5 Class I HLA-A,-B, and -C genotypes of 175 samples from Kampilaa, Uganda, used for assay validation.  
Found at: doi:10.1371/journal.pone.0010751.s005 (0.04 MB XLS)

Table S6 Examples of expected and observed reactivity patterns for non-addressed genotypes. See text for details.  
Found at: doi:10.1371/journal.pone.0010751.s006 (0.03 MB XLS)

Table S7 Performance of typing platform on the complete sample set from Kampala, Uganda (n = 175).  
Found at: doi:10.1371/journal.pone.0010751.s007 (0.06 MB DOC)

Table S8 Allele frequencies for class I HLA-A,-B, and -C in Mbeya, Tanzania (2n = 348). Only alleles addressed by the current SSP-real-time PCR assay are listed. See text for details.  
Found at: doi:10.1371/journal.pone.0010751.s008 (0.06 MB DOC)

Table S9 Observed genotypes in Tanzania (n = 174) did not significantly differ from those expected under Hardy-Weinberg equilibrium.  
Found at: doi:10.1371/journal.pone.0010751.s009 (0.09 MB DOC)

Figure S1 Locus-specific pre-amplification is necessary for optimal performance of SSP-real time PCR-based HLA typing.  
Performance of reaction HLA-B016 (which is specific for HLA-B*0702, HLA-B*0801, HLA-B*1402, HLA-B*1503, HLA-B*1510, HLA-B*1801, HLA-B*4201, HLA-B*4202, and HLA-B*8101) on Ugandan samples a) before, and b) after subjecting to HLA-B-specific PCR pre-amplification. Red circles and black crosses depict carriers and non-carriers of the addressed polymorphisms, respectively. Non-template controls are depicted by triangles. See text for details.  
Found at: doi:10.1371/journal.pone.0010751.s010 (1.55 MB TIF)

Figure S2 Carrier frequencies of major class I HLA alleles in East African populations. Carrier frequencies of alleles addressed by the current platform are shown for the Kenyan Highlander [Nandi] [32] (yellow), Kenyan Lowlander [Luo] (orange) [32], Uganda (green) and the current Tanzanian population (red).  
Found at: doi:10.1371/journal.pone.0010751.s011 (0.73 MB TIF)

Figure S3 Principal component analysis showing the location of the Mbeya, Tanzania population in the context of global class I HLA genetic diversity. Principal component analysis (PCA) based on genetic distances in HLA-A,-B, and -C loci. Reference world populations were retrieved from the dbMHC [75]. In interest of clarity, only the first and second principal components are shown, which account for 79.4% of the variance. The composition of the outlined sub-Saharan cluster is shown in detail in the inset. The expanded box shows a close up the sub-Saharan populations. Populations are labeled as follows: 1: American Samoan (American Samoa, United States), 2: Amerindian (United States), 3: Ami97 (Taiwan), 4: ArabDruze (Israel), 5: Atayal (Taiwan), 6: Bari (Venezuela), 7: Brazilian Admixed (Brazil), 8: Bulgarian (Bulgaria), 9: Bunun (Taiwan), 10: Canoncito (New Mexico, United States), 11: Cape York (Australia), 12: Chinese (China), 14: Mbeya (Tanzania), 16: Czech (Czech Republic), 17: Doggon (Mali), 18: Filipino (Philippines), 19: Finno90 (Finland), 20: Georgian (Georgia), 21: GrooteEylandt (Australia), 22: Guarani-Kaioawa (Brazil), 23: Guarani-Nandewa (Brazil), 24: Hakka (Taiwan), 25: Irish (Ireland), 26: IsraeliJew (Israel), 27: Ivatan (Philippines), 28: JavaneseIndonesian (Singapore), 29: Kenyan42 (Kenya), 30: KenyanHighlander (Kenya), 31: KenyanLowlander (Kenya), 32: Kimberley (Australia), 33: Korean200 (South Korea), 34: Kurdish (Georgia), 35: Malay (Singapore), 36: Minnan (Taiwan), 37: NewDelhi (India), 38: African American (United States), 39: Asian American (United States), 40: Caucasian (United States), 41: Hispanic (United States), 42: Okinawan (United States), 43: Paiwan51 (Taiwan), 44: Pazeh (Taiwan), 45: Puyuma49 (Taiwan), 46: Rukai (Taiwan), 47: Kamplaa, Uganda (Uganda), 48: Saisiat (Taiwan), 49: Shona (Zimbabwe), 50: Siraya (Taiwan), 51: Tamil (South Africa), 52: Thai (Taiwan), 53: Thao (Taiwan), 54: Toroko (Taiwan), 55: Tsou (Taiwan), 56: Tuva (Taiwan), 57: Xam (Taiwan), 58: Yami (Taiwan), 59: Yuendumu (Australia), 60: Yupik (Alaska, United States), 61: Zambian (Zambia), 62: Zulu (South Africa). See text for details.  
Found at: doi:10.1371/journal.pone.0010751.s012 (1.26 MB TIF)

Figure S4 Dendrogram showing the location of the Mbeya, Tanzania population in the context of global class I HLA genetic diversity. The unrooted dendrogram was built using combined HLA-A,-B, -C allele frequency derived genetic distances. The
References

1. Rimmelzwaan GF, Fouchier RA, Osterhaus AD (2007) Influenza virus-specific cytotoxic T lymphocytes: a correlate of protection and a basis for vaccine development. Curr Opin Biotechnol 18: 529–536.

2. Stenger S (2001) Cytolytic T cells in the immune response to mycobacterium tuberculosis. Scand J Infect Dis 33: 493–497.

3. Parham P (2005) MHCI class I molecules and KIRs in human history, health and survival. Nat Rev Immunol 5: 201–214.

4. International HapMap Consortium (2005) A haplotype map of the human genome. Nature 437: 1299–1320.

5. Anthony Nolan Research Institute (2009) Full List of HLA Class I Alleles Assigned July 2009.

6. Solberg OD, Mack SJ, Lancaster AK, Single RM, Tsai Y, et al. (2008) Balancing selection and heterogeneity across the classical human leucocyte antigen loci: a meta-analytic review of 497 population studies. Hum Immunol 69: 443–464.

7. Hughes AL, Yeager M (1998) Natural selection at major histocompatibility complex loci. Genetics 124: 967–972.

8. Stoneking M, Linen C, Doryan CF, Quennel LF, Chasman D, et al. (1994) Mitochondrial DNA HLA-B*1501 and HLA-B*4402. Tissue Antigens 53: 305–310.

9. World Health Organization (2006) Outbreak of Marburg haemorrhagic fever in Uganda. June–August 2007. WEEKLY EPIDEMIOLOGICAL RECORD 82: 301–304.

10. World Health Organization (2007) Rift Valley Fever in Kenya, Somalia and the United Republic of Tanzania.

11. World Health Organization (2007) Ebola haemorrhagic fever in Uganda.

12. Hill AV, Allopp CE, Kwiatkowski D, Amesty NM, Twumai P, et al. (1991) Common west African HLA antigens are associated with protection from severe malaria. Nature 352: 595–600.

13. Hill AV, Yates SN, Allopp CE, Gupta S, Gilbert SC, et al. (1994) Human leucocyte antigens and natural selection by malaria. Philos Trans R Soc Lond B Biol Sci 346: 579–587.

14. Kettaneh A, Seng L, Tsep K, Toleldano C, Faire F, et al. (2006) Human leucocyte antigens and susceptibility to tuberculosis: a meta-analysis of case-control studies. Int J Tubercul Lung Dis 10: 717–725.

15. Raja A (2004) Immunoology of tuberculosis. Indian J Med Res 120: 213–232.

16. Basu R, Roy S, Walden P (2007) HLA class I-restricted T cell epitopes of the kinetoplastid membrane protein-11 presented by Leishmania donovani-infected human macrophages. J Infect Dis 195: 1373–1380.

17. Sanchez A, Wagenen KE, Rollin PE (2007) Sequence-based human leucocyte antigen-B typing of patients infected with Ebola virus in Uganda in 2000: identification of alleles associated with fatal and nonfatal disease outcomes. J Infect Dis 196 Suppl 2: S239–S336.

18. Abdel-Salam E, Abdel Khalik A, Abdel-Meguid A, Barakat W, Mahmoud AA (1986) Association of HLA class I antigens (A1, B5, Bw and CW) with disease manifestations and infection in human schistosomiasis mansoni in Egypt. Tissue Antigens 27: 142–146.

19. Leslie AJ, Price DA, Mkhize P, Bishop K, Rashid A, et al. (2006) Differential selection pressure exerted on HIV by CTL targeting identical epitopes but restricted by distinct HLA alleles from the same HLA supertype. J Immunol 177: 4609–4708.

20. Khanuja P, Leslie AJ, Honyborne I, Ramduth D, Thobakgale C, et al. (2006) Strong influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature 432: 769–775.

21. Koo KM, Moormann AM, Lyke KE, Masuberg C, Sumba OP, et al. (2004) Differentiation between African populations is evidenced by the diversity of alleles and haplotypes of HLA class I loci. Tissue Antigens 63: 293–325.

22. Kijak GH, Walsh AM, Koehler RN, Moquet N, Eller LA, et al., 2009) HLA I and allele heterogeneity in Uganda supports the presence of a major east African genetic cluster. Tissue Antigens 73: 262–269.

23. Ellis JM, Mack SJ, Leke RF, Quayk I, Johnson AH, et al. (2000) Diversity is demonstrated in class I HLA-A and HLA-B alleles in Cameroon, Africa: description of HLA-A*0301, *0306 and HLA-B*07, *0311, *0401. Tissue Antigens 56: 291–292.

24. Louie LG, Hartogensis WE, Jackman RP, Schultz KA, Zijenah LS, et al. (2004) Mycobacterium tuberculosis/HIV-1 coinfection and disease: role of human leucocyte antigen variation. J Infect Dis 189: 1084–1090.

25. Loo M, Embree J, Ramdath N, Ndhlovu-Cholo J, Nyanga S, et al. (2002) HLA-A and HLA-B in Kenya, Africa: allele frequencies and identification of HLA-B*1502 and HLA-B*4442. Tissue Antigens 59: 307–310.

26. Middleton D, Williams F, Meenagh A, Daar AS, Gorodezky C, et al. (2000) Analysis of the distribution of HLA-A alleles in populations from five continents. Hum Immunol 61: 1048–1052.

27. Sanchez-Mazas A, Steiner GQ, Grundschuber C, Tierney JM (2000) The molecular determination of HLA-Cw alleles in the Mandenka (West Africa)

Acknowledgments

The authors would like to thank Mr. Ola Oloso Usunde and Mrs. Nasheed Moquet at the U.S. military HIV research program, Rockville, MD for their technical assistance. The views and opinions expressed herein do not necessarily reflect those of the U.S. Army, the Department of Defense or the National Institutes of Health.
reveals a close genetic relationship between Africans and Europeans. Tissue Antigens 56: 303–312.

39. Tang J, Naik E, Costello C, Karita E, Rivers C, et al. (2000) Characteristics of HLA class I and class II polymorphisms in Rwandan women. Exp Clin Immunogenet 17: 185–196.

40. Williams F, Meenagh A, Darke C, Acosta A, Daar AS, et al. (2001) Analysis of the distribution of HLA-B alleles in populations from five continents. Hum Immunol 62: 645–650.

41. Brandler C, Frahm N, Walker BD (2006) The challenges of host and viral diversity in HIV vaccine design. Curr Opin Immunol 18: 430–437.

42. Burton PR, Hansell AL, Fortier I, Manolito TA, Khoury MJ, et al. (2009) Size matters: just how big is BIG? Quantifying realistic sample size requirements for human genome epidemiology. Int J Epidemiol 38: 263–273.

43. Adams SD, Barracchini KC, Chen D, Robbins F, Wang L, et al. (2004) Ambiguous allele combinations in HLA Class I and Class II sequence-based typing when precise nucleotide sequencing leads to imprecise allele identification. J Transl Med 2: 30.

44. Browning MJ, Kraupa P, Rowan A, Bicknell DG, Bodmer JG, et al. (1993) Tissue typing the HLA-A locus from genomic DNA by sequence-specific PCR: comparison of HLA-A genotype and surface expression on colorectal tumor cell lines. Proc Natl Acad Sci USA 90: 2942–2945.

45. Trachtenberg E, Korbet B, Sollars C, Kepler TB, Hraber PT, et al. (2003) Advantage of rare HLA supertype in HIV disease progression. Nat Med 9: 920–925.

46. Cerber N, Maye P, Lee S, Kong Y, Yang SY (1995) Locus-specific amplification of HLA class I genes from genomic DNA: locus-specific sequences in the first and third introns of HLA-A, -B, and -C alleles. Tissue Antigens 45: 1–11.

47. Kochler RN, Walsh AM, Mosquet N, Currier JR, Eller MA, et al. (2009) High-throughput genotyping of KIR2DL2/L3, KIR2DL3/S1, and their HLA class I ligands using real-time PCR. Tissue Antigens 74: 73–80.

48. Robinson J, Marsh SG (2007) iPD: the Immuno Polymorphism Database. Methods Mol Biol 409: 61–74.

49. Cavalli-Sforza LL, Edwards AW (1967) Phylogenetic analysis. Models and estimation procedures. Am J Hum Genet 19: 233–257.

50. Cavalli-Sforza L, Bodmer WF (1971) The Genetics of Human Populations. San Francisco, CA: W.H. Freeman.

51. Middleton E, Mouchacca L, Rood H, Komorosky R (2003) New allele frequency database: http://www.allerefrequencies.net. Tissue Antigens 61: 403–407.

52. Luedde H, Blaszyk R (1997) Fluorotyping of HLA-C: differential detection of allele specific priming and fluorogenic probing. Tissue Antigens 50: 627–638.

53. Slaton K, Camps MA, Blaszyk R (1998) Fluorotyping of HLA-A by sequence-specific priming and fluorogenic probing. Tissue Antigens 52: 462–472.

54. Lenzert K, Pacham P (1996) Evolution of MHC class I genes in higher primates. Immunol Cell Biol 74: 349–356.

55. Xiang Q, Xu B, Fu R, Li D (2005) Real time PCR on disposable PDMS chip with a miniaturized thermal cycler. Biomed Microdevices 7: 273–279.

56. Walczak R, Dziuban JA, Koszur J, Bang DD, Ruano-Lopez J (2008) Tissue typing the HLA-A locus from genomic DNA by sequence-specific PCR: comparison of HLA-A genotype and surface expression on colorectal tumor cell lines. Proc Natl Acad Sci USA 90: 2942–2945.

57. Tishkoff SA, Reed FA, Friedlaender FR, Ehret C, Ranciaro A, et al. (2009) The genetic structure and history of Africans and African Americans. Science 324: 1035–1044.

58. Arroyo MA, Hoelscher M, Sateren W, Samky E, Maboko L, et al. (2005) HIV-1 diversity and prevalence differ between urban and rural areas in the Mbeya region of Tanzania. Aids 19: 1517–1524.

59. Arroyo MA, Sateren WB, Serwadda D, Gray RH, Wasew MJ, et al. (2006) Higher HIV-1 incidence and genetic complexity along main roads in Rakai District, Uganda. J Acquir Immune Defic Syndr 43: 440–445.

60. Dowling WE, Kim B, Mason CJ, Wasawna KM, Alam U, et al. (2002) Forty-one near full-length HIV-1 sequences from Kenya reveal an epidemic of subtype A and A-containing recombinants. Aids 16: 1809–1820.

61. Harris ME, Serwadda D, Sewankambo N, Kim B, Kigozi G, et al. (2002) Among 46 near full length HIV-1 genome sequences from Rakai District, Uganda, subtype D and AD recombinants predominate. AIDS Res Hum Retroviruses 18: 1281–1290.

62. Hoelscher M, Kim B, Maboko L, Mihal J, von Sonnenburg F, et al. (2001) High proportion of unrelated HIV-1 intersubtype recombinants in the Mbeya region of southwest Tanzania. Aids 15: 1461–1470.

63. Leslie A, Kavanagh D, Honeyborne I, Pfafferott K, Edwards C, et al. (2002) Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 296: 1439–1443.

64. Moore CB, John M, James IR, Christiansen FT, Witt CS, et al. (2002) Diversity in HLA class I allele promiscuity among viral CTL epitopes. Eur J Immunol 37: 2419–2433.

65. Frahm N, Yani K, Sowolowicz TJ, Adams S, Sidney J, et al. (2007) Extensive polymorphism of HLA class I alleles in South Africa. Tissue Typing 1: 1–12.

66. Harari A, Bert PA, Stohr W, Taiapa G, Garcia M, et al. (2008) An HIV-1 clade C DNA prime, NYYAC boost vaccine regimen induces reduced binding, polyfunctional, and long-lasting T cell responses. J Exp Med 205: 63–77.

67. Kawashima Y, Pfafferott K, Frater J, Mathews P, Payne R, et al. (2009) Adaptation of HIV-1 to human leucocyte antigen class I. Nature 458: 641–645.

68. Robinson J, Waller MJ, Fail SC, McWilliam H, Lopez R, et al. (2009) The IMGT/HLA database. Nucleic Acids Res 37: D1013–1017.

69. Thompson JD, Gibson TJ, Pleasance E, Kornberg R, Higgins DG (1997) The CLUSTAL X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res 25: 4876–4880.

70. Smith SW, Overbeek R, Woese CR, Gillevet PM (1994) The genetic data environment an expandable GUI for multiple sequence analysis. Comput Appl Biosci 10: 671–675.

71. Mouritzen P, Nielsen AT, Phunheller HM, Choeva Y, Kongsbak L, et al. (2003) Single nucleotide polymorphism genotyping using locked nucleic acid (LNA) primers. Hum Mutant 22: 79–85.

72. Lesir A, Kavanagh D, Honeyborne I, Pfafferott K, Edwards C, et al. (2005) Single nucleotide polymorphism genotyping using locked nucleic acid (LNA) primers. Hum Mutant 22: 79–85.

73. Altman DG, Bland JM (1994) Diagnostic tests. 1: Sensitivity and specificity. BMJ 308: 1532.

74. Altman DG, Bland JM (1994) Diagnostic tests 2: Predictive values. BMJ 309: 102.

75. Kins A, Feo M, Helmberg W (2003) The Major Histocompatibility Complex Database, dbMHC. In: National Center for Biotechnology Information NIH. editor. The NCBI Handbook. Bethesda, MD.

76. Redon R, Ishikawa S, Fitch KR, Fruk L, Perry GH, et al. (2006) Global variation in copy number in the human genome. Nature 444: 444–445.

77. Felsenstein J (1989) PHYLIP - Phylogeny Inference Package (Version 3.2). Cladistics 5: 164–166.

78. Saitou N, Nei M (1987) The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol 4: 406–425.

79. Tamura K, Dudley J, Nei M, Kumar S (2007) MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 24: 1596–1599.